Becker's Healthcare August 15, 2024
Elizabeth Gregerson

The antiviral drug tecovirimat did not reduce the duration of mpox lesions in a randomized, placebo-controlled trial.

The results were studied among children and adults with mpox in the Democratic Republic of the Congo, according to an Aug. 15 news release from the National Institutes of Health. Detailed results will be released through scientific channels, the NIH said.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Duquesne, CVS debut tuition program to train pharmacists

Share This Article